61310 Federal Register / Vol. 70, No. 203 / Friday, October 21, 2005 / Notices 

SUMMARY: Notice is hereby given that 

the U.S. International Trade 

Commission has determined to review 

in part an initial determination (‘‘ID’’) of 

the presiding administrative law judge 

(‘‘ALJ’’) finding no violation of section 

337 of the Tariff Act of 1930, as 

amended, in the above-captioned 

investigation. The Commission 

determined on review to decline to 

reach the issue of whether one claim 

term was met by the accused pool cues. 

The Commission has determined not to 

review the ALJ’s determination that one 

other limitation of the claims at issue is 

not met by the accused products. The 

investigation is therefore terminated 

with a finding of no violation. 

FOR FURTHER INFORMATION CONTACT: 

Michael K. Haldenstein, Esq., Office of 

the General Counsel, U.S. International 

Trade Commission, 500 E Street, SW., 

Washington, DC 20436, telephone (202) 

205–3041. Copies of the public version 

of the ALJ’s ID and all other 

nonconfidential documents filed in 

connection with this investigation are or 

will be available for inspection during 

official business hours (8:45 a.m. to 5:15 

p.m.) in the Office of the Secretary, U.S. 

International Trade Commission, 500 E 

Street, SW., Washington, DC 20436, 

telephone 202–205–2000. 

General information concerning the 

Commission may also be obtained by 

accessing its Internet server (http:// 

www.usitc.gov). The public record for 

this investigation may be viewed on the 

Commission’s electronic docket (EDISON-LINE) at http://edis.usitc.gov. 

Hearing-impaired persons are advised 

that information on this matter can be 

obtained by contacting the 

Commission’s TDD terminal on (202) 

205–1810. 

SUPPLEMENTARY INFORMATION: The 

Commission instituted the abovereferenced investigation under section 

337 of the Tariff Act of 1930 on April 

4, 2005, based on a complaint filed by 

J. Pechauer Custom Cues, Inc. 

(‘‘Pechauer’’) of Green Bay, Wisconsin. 

70 FR 7112. The complaint alleged 

infringement of U.S. Patent No. 

6,582,317 (the ‘317 patent), in the 

importation, sale for importation, and 

sale within the United States after 

importation of certain pool cues covered 

by all 29 claims of the ‘317 patent. The 

Commission named the following 

companies as respondents in the 

investigation: Kaokao Industrial Co. 

LTD., aka Kaokao (Zhang Zhou) Sports 

(‘‘Kao Kao’’) Equipment Co. Ltd. of 

Taiwan; CueStix International of 

Lafayette, Colorado; Sterling Gaming of 

Matthews, North Carolina; CueSight of 

Matthews, North Carolina; Imperial 

International of Hasbrouck Heights, 

New Jersey; Sigel’s Unlimited Cues & 

Accessories of Winter Garden, Florida; 

Nick Varner Cues and Cases of 

Owensboro, Kentucky; J–S Sales Co. Inc. 

of Elmsford, New York; and GLD 

Products of Muskego, Wisconsin. 

On September 1, 2005, the ALJ issued 

an ID (Order No. 5) granting Kao Kao’s 

motion for summary determination of 

noninfringement and finding that Kao 

Kao’s accused pool cues do not satisfy 

two limitations of the two independent 

claims of the ‘317 patent. On September 

7, 2005, complainant Pechauer filed a 

petition for review of the ALJ’s ID, and 

on September 19, 2005, the Commission 

Investigative Attorney and Kao Kao filed 

oppositions to Pechauer’s petition for 

review. On September 22, 2005, the 

Commission extended the time for 

deciding whether to review the ID until 

October 17, 2005. 

Having examined the record in this 

investigation, including the ID, the 

petition for review, and the responses 

thereto, the Commission has determined 

not to review the portion of the ID 

concerning the ‘‘slightly threaded 

anterior portion’’ limitation. The 

Commission has determined to review, 

and on review, to decline to reach the 

issue of whether the accused pool cues 

meet the ‘‘closed posterior end’’

limitation. Accordingly, the 

investigation is terminated with a 

finding of no violation. 

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and in sections 210.42 of the 

Commission’s Rules of Practice and 

Procedure (19 CFR 210.42). 

By order of the Commission. 

Issued: October 18, 2005. 

Marilyn R. Abbott, 

Secretary to the Commission. 

[FR Doc. 05–21108 Filed 10–20–05; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–270P] 

Controlled Substances: Proposed 

Aggregate Production Quotas for 2006 

AGENCY: Drug Enforcement 

Administration (DEA), Justice. 

ACTION: Notice of proposed year 2006 

aggregate production quotas. 

SUMMARY: This notice proposes initial 

year 2006 aggregate production quotas 

for controlled substances in Schedules I 

and II of the Controlled Substances Act 

(CSA). 

DATES: Comments or objections must be 

received on or before November 14, 

2005. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–270P’’ on all written and 

electronic correspondence. Written 

comments being sent via regular mail 

should be sent to the Deputy Assistant 

Administrator, Office of Diversion 

Control, Drug Enforcement 

Administration, Washington, DC 20537, 

Attention: DEA Federal Register 

Representative/ODL. Written comments 

sent via express mail should be sent to 

DEA Headquarters, Attention: DEA 

Federal Register Representative/ODL, 

2401 Jefferson-Davis Highway, 

Alexandria, VA 22301. Comments may 

be directly sent to DEA electronically by 

sending an electronic message to 

dea.diversion.policy@usdoj.gov. 

Comments may also be sent 

electronically through http:// 

www.regulations.gov using the 

electronic comment form provided on 

that site. An electronic copy of this 

document is also available at the 

http://www.regulations.gov Web site. 

DEA will accept attachments to 

electronic comments in Microsoft Word, 

WordPerfect, Adobe PDF, or Excel file 

formats only. DEA will not accept any 

file format other than those specifically 

listed here. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, Ph.D., Chief, 

Drug and Chemical Evaluation Section, 

Drug Enforcement Administration, 

Washington, DC 20537, Telephone: 

(202) 307–7183. 

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in Schedules I and II. This 

responsibility has been delegated to the 

Administrator of the DEA by section 

0.100 of Title 28 of the Code of Federal 

Regulations. The Administrator, in turn, 

has redelegated this function to the 

Deputy Administrator, pursuant to 

section 0.104 of Title 28 of the Code of 

Federal Regulations. 

The proposed year 2006 aggregate 

production quotas represent those 

quantities of controlled substances that 

may be produced in the United States in 

2006 to provide adequate supplies of 

each substance for: The estimated 

medical, scientific, research, and 

industrial needs of the United States; 

lawful export requirements; and the 

establishment and maintenance of 

reserve stocks. These quotas do not 

Federal Register / Vol. 70, No. 203 / Friday, October 21, 2005 / Notices 61311 

include imports of controlled 

substances for use in industrial 

processes. 

In determining the proposed year 

2006 aggregate production quotas, the 

Deputy Administrator considered the 

following factors: Total actual 2004 and 

estimated 2005 and 2006 net disposals 

of each substance by all manufacturers; 

estimates of 2005 year-end inventories 

of each substance and of any substance 

manufactured from it and trends in 

accumulation of such inventories; 

product development requirements of 

both bulk and finished dosage form 

manufacturers; projected demand as 

indicated by procurement quota 

applications filed pursuant to Section 

1303.12 of Title 21 of the Code of 

Federal Regulations; and other pertinent 

information. 

Pursuant to section 1303 of Title 21 of 

the Code of Federal Regulations, the 

Deputy Administrator of the DEA will, 

in early 2006, adjust aggregate 

production quotas and individual 

manufacturing quotas allocated for the 

year based upon 2005 year-end 

inventory and actual 2005 disposition 

data supplied by quota recipients for 

each basic class of Schedule I or II 

controlled substance. 

Therefore, under the authority vested 

in the Attorney General by section 306 

of the CSA of 1970 (21 U.S.C. 826), and 

delegated to the Administrator of the 

DEA by section 0.100 of Title 28 of the 

Code of Federal Regulations, and 

redelegated to the Deputy Administrator 

pursuant to section 0.104 of Title 28 of 

the Code of Federal Regulations, the 

Deputy Administrator hereby proposes 

that the year 2006 aggregate production 

quotas for the following controlled 

substances, expressed in grams of 

anhydrous acid or base, be established 

as follows: 

Basic class—schedule I Proposed year 

2006 quotas 

2,5-Dimethoxyamphetamine ............................................................................................................................................................. 2,801,000 g 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ................................................................................................................................... 2 g 

3-Methylfentanyl ................................................................................................................................................................................ 2 g 

3-Methylthiofentanyl .......................................................................................................................................................................... 2 g 

3,4-Methylenedioxyamphetamine (MDA) ......................................................................................................................................... 15 g 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .......................................................................................................................... 5 g 

3,4-Methylenedioxymethamphetamine (MDMA) .............................................................................................................................. 17 g 

3,4,5-Trimethoxyamphetamine ......................................................................................................................................................... 2 g 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................................................................... 2 g 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ............................................................................................................................... 2 g 

4-Methoxyamphetamine ................................................................................................................................................................... 5 g 

4-Methylaminorex ............................................................................................................................................................................. 2 g 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................................................................... 2 g 

5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................................................................... 2 g 

Acetyl-alpha-methylfentanyl .............................................................................................................................................................. 2 g 

Acetyldihydrocodeine ........................................................................................................................................................................ 2 g 

Acetylmethadol ................................................................................................................................................................................. 2 g 

Allylprodine ....................................................................................................................................................................................... 2 g 

Alphacetylmethadol ........................................................................................................................................................................... 2 g 

Alpha-ethyltryptamine ....................................................................................................................................................................... 2 g 

Alphameprodine ................................................................................................................................................................................ 2 g 

Alphamethadol .................................................................................................................................................................................. 3 g 

Alpha-methylfentanyl ........................................................................................................................................................................ 2 g 

Alpha-methylthiofentanyl ................................................................................................................................................................... 2 g 

Aminorex ........................................................................................................................................................................................... 2 g 

Benzylmorphine ................................................................................................................................................................................ 2 g 

Betacetylmethadol ............................................................................................................................................................................ 2 g 

Beta-hydroxy-3-methylfentanyl ......................................................................................................................................................... 2 g 

Beta-hydroxyfentanyl ........................................................................................................................................................................ 2 g 

Betameprodine .................................................................................................................................................................................. 2 g 

Betamethadol .................................................................................................................................................................................... 2 g 

Betaprodine ....................................................................................................................................................................................... 2 g 

Bufotenine ......................................................................................................................................................................................... 2 g 

Cathinone .......................................................................................................................................................................................... 2 g 

Codeine-N-oxide ............................................................................................................................................................................... 252 g 

Diethyltryptamine .............................................................................................................................................................................. 2 g 

Difenoxin ........................................................................................................................................................................................... 5,000 g 

Dihydromorphine ............................................................................................................................................................................... 1,826,000 g 

Dimethyltryptamine ........................................................................................................................................................................... 3 g 

Gamma-hydroxybutyric acid ............................................................................................................................................................. 8,000,000 g 

Heroin ............................................................................................................................................................................................... 2 g 

Hydromorphinol ................................................................................................................................................................................. 2 g 

Hydroxypethidine .............................................................................................................................................................................. 2 g 

Lysergic acid diethylamide (LSD) ..................................................................................................................................................... 61 g 

Marihuana ......................................................................................................................................................................................... 4,500,000 g 

Mescaline .......................................................................................................................................................................................... 2 g 

Methaqualone ................................................................................................................................................................................... 5 g 

Methcathinone .................................................................................................................................................................................. 4 g 

Methyldihydromorphine ..................................................................................................................................................................... 2 g 

Morphine-N-oxide ............................................................................................................................................................................. 252 g 

N,N-Dimethylamphetamine ............................................................................................................................................................... 2 g 

N-Ethylamphetamine ........................................................................................................................................................................ 2 g 

N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................................... 2 g 

Noracymethadol ................................................................................................................................................................................ 2 g 

Norlevorphanol .................................................................................................................................................................................. 52 g 

61312 Federal Register / Vol. 70, No. 203 / Friday, October 21, 2005 / Notices 

Basic class—schedule I Proposed year 

2006 quotas 

Normethadone .................................................................................................................................................................................. 2 g 

Normorphine ..................................................................................................................................................................................... 12 g 

Para-fluorofentanyl ............................................................................................................................................................................ 2 g 

Phenomorphan ................................................................................................................................................................................. 2 g 

Pholcodine ........................................................................................................................................................................................ 2 g 

Psilocybin .......................................................................................................................................................................................... 2 g 

Psilocyn ............................................................................................................................................................................................. 7 g 

Tetrahydrocannabinols ..................................................................................................................................................................... 312,500 g 

Thiofentanyl ...................................................................................................................................................................................... 2 g 

Trimeperidine .................................................................................................................................................................................... 2 g 

Basic class—schedule II Proposed year 

2006 quotas 

1-Phenylcyclohexylamine ................................................................................................................................................................. 2 g 

Alfentanil ........................................................................................................................................................................................... 2,500 g 

Alphaprodine ..................................................................................................................................................................................... 2 g 

Amobarbital ....................................................................................................................................................................................... 2 g 

Amphetamine .................................................................................................................................................................................... 14,500,000 g 

Cocaine ............................................................................................................................................................................................. 228,000 g 

Codeine (for sale) ............................................................................................................................................................................. 39,605,000 g 

Codeine (for conversion) .................................................................................................................................................................. 55,000,000 g 

Dextropropoxyphene ......................................................................................................................................................................... 167,365,000 g 

Dihydrocodeine ................................................................................................................................................................................. 750,000 g 

Diphenoxylate ................................................................................................................................................................................... 828,000 g 

Ecgonine ........................................................................................................................................................................................... 73,000 g 

Ethylmorphine ................................................................................................................................................................................... 2 g 

Fentanyl ............................................................................................................................................................................................ 1,428,000 g 

Glutethimide ...................................................................................................................................................................................... 2 g 

Hydrocodone (for sale) ..................................................................................................................................................................... 37,604,000 g 

Hydrocodone (for conversion) .......................................................................................................................................................... 1,500,000 g 

Hydromorphone ................................................................................................................................................................................ 3,300,000 g 

Isomethadone ................................................................................................................................................................................... 2 g 

Levo-alphacetylmethadol (LAAM) ..................................................................................................................................................... 2 g 

Levomethorphan ............................................................................................................................................................................... 2 g 

Levorphanol ...................................................................................................................................................................................... 5,000 g 

Meperidine ........................................................................................................................................................................................ 9,753,000 g 

Metazocine ........................................................................................................................................................................................ 1 g 

Methadone (for sale) ........................................................................................................................................................................ 15,490,000 g 

Methadone Intermediate ................................................................................................................................................................... 19,208,000 g 

Methamphetamine ............................................................................................................................................................................ 2,340,000 g 

[680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,615,000 grams for methamphetamine 

mostly for conversion to a Schedule III product; and 45,000 grams for methamphetamine (for sale)] 

Methylphenidate ................................................................................................................................................................................ 35,000,000 g 

Morphine (for sale) ........................................................................................................................................................................... 35,000,000 g 

Morphine (for conversion) ................................................................................................................................................................. 110,774,000 g 

Nabilone ............................................................................................................................................................................................ 2 g 

Noroxymorphone (for sale) ............................................................................................................................................................... 1,002 g 

Noroxymorphone (for conversion) .................................................................................................................................................... 4,000,000 g 

Opium ............................................................................................................................................................................................... 1,280,000 g 

Oxycodone (for sale) ........................................................................................................................................................................ 49,200,000 g 

Oxycodone (for conversion) ............................................................................................................................................................. 920,000 g 

Oxymorphone ................................................................................................................................................................................... 534,000 g 

Pentobarbital ..................................................................................................................................................................................... 18,251,000 g 

Phencyclidine .................................................................................................................................................................................... 2,006 g 

Phenmetrazine .................................................................................................................................................................................. 2 g 

Racemethorphan .............................................................................................................................................................................. 2 g 

Remifentanil ...................................................................................................................................................................................... 1,800 g 

Secobarbital ...................................................................................................................................................................................... 2 g 

Sufentanil .......................................................................................................................................................................................... 4,000 g 

Thebaine ........................................................................................................................................................................................... 72,453,000 g 

The Deputy Administrator further 

proposes that aggregate production 

quotas for all other Schedules I and II 

controlled substances included in 

sections 1308.11 and 1308.12 of Title 21 

of the Code of Federal Regulations be 

established at zero. 

All interested persons are invited to 

submit their comments in writing or 

electronically regarding this proposal 

following the procedures in the 

ADDRESSES section of this document. A 

person may object to or comment on the 

proposal relating to any of the abovementioned substances without filing 

comments or objections regarding the 

others. If a person believes that one or 

more of these issues warrant a hearing, 

the individual should so state and 

summarize the reasons for this belief. 

Federal Register / Vol. 70, No. 203 / Friday, October 21, 2005 / Notices 61313 

In the event that comments or 

objections to this proposal raise one or 

more issues which the Deputy 

Administrator finds warrant a hearing, 

the Deputy Administrator shall order a 

public hearing by notice in the Federal 

Register, summarizing the issues to be 

heard and setting the time for the 

hearing. 

The Office of Management and Budget 

has determined that notices of aggregate 

production quotas are not subject to 

centralized review under Executive 

Order 12866. 

This action does not preempt or 

modify any provision of state law; nor 

does it impose enforcement 

responsibilities on any state; nor does it 

diminish the power of any state to 

enforce its own laws. Accordingly, this 

action does not have federalism 

implications warranting the application 

of Executive Order 13132. 

The Deputy Administrator hereby 

certifies that this action will have no 

significant impact upon small entities 

whose interests must be considered 

under the Regulatory Flexibility Act, 5 

U.S.C. 601 et seq. The establishment of 

aggregate production quotas for 

Schedules I and II controlled substances 

is mandated by law and by international 

treaty obligations. The quotas are 

necessary to provide for the estimated 

medical, scientific, research and 

industrial needs of the United States, for 

export requirements and the 

establishment and maintenance of 

reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by State, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $115,000,000 or more 

in any one year, and will not 

significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

This action is not a major rule as 

defined by section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996. This action will 

not result in an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 

Dated: October 14, 2005. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. 05–21038 Filed 10–20–05; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Federal Bureau of Investigation 

Meeting of the CJIS Advisory Policy 

Board 

AGENCY: Federal Bureau of Investigation 

(FBI). 

ACTION: Meeting notice. 

SUMMARY: The purpose of this notice is 

to announce the meeting of the Criminal 

Justice Information Services (CJIS) 

Advisory Policy Board (APB). The CJIS 

APB is responsible for reviewing policy 

issued and appropriate technical and 

operational issues related to the 

programs administered by the FBI’s CJIS 

Division, and thereafter, making 

appropriate recommendations to the FBI 

Director. The programs administered by 

the CJIS Division are the Integrated 

Automated Fingerprint Identification 

System, the Interstate Identification 

System, the Interstate Identification 

Index, Law Enforcement Online, 

National Crime Information Center, the 

National Instant Criminal Background 

Check System, the National IncidentBased Reporting System, Law 

Enforcement National Data Exchange, 

and Uniform Crime Reporting. 

The meeting will be open to the 

public on a first-come, first-seated basis. 

Any member of the public wishing to 

file a written statement concerning the 

CJIS Division programs or wishing to 

address this session should notify 

Senior CJIS Advisor Roy G. Weise at 

(304) 625–2730 at least 24 hours prior 

to the start of the session. 

The notification should contain the 

requestor’s name, corporate designation, 

and consumer affiliation or government 

designation along with a short statement 

describing the topic to be addressed and 

the time needed for the presentation. A 

requestor will ordinarily be allowed no 

more than 15 minutes to present a topic. 

DATES: The APB will meet in open 

session from 8:30 a.m. until 5 p.m., on 

December 7–8, 2005. 

ADDRESSES: The meeting will take place 

at The Rosen Centre Hotel, 9840 

International Drive, Orlando, Florida 

(407) 996–9840. 

FOR FURTHER INFORMATION CONTACT: 

Inquiries may be addressed to Mrs. 

Kimberly S. Parsons, Management 

Analyst, Advisory Groups Management 

Unit, Programs Development Section, 

FBI CJIS Division, Module C3, 1000 

Custer Hollow Road, Clarksburg, West 

Virginia 26306–0149, telephone (304) 

625–2404, facsimile (304) 625–5090. 

Dated: October 17, 2005. 

Roy G. Weise, 

Senior CJIS Advisor, Criminal Justice 

Information Service Division, Federal Bureau 

of Investigation. 

[FR Doc. 05–21057 Filed 10–20–05; 8:45 am] 

BILLING CODE 4410–02–M 

DEPARTMENT OF LABOR 

Office of the Secretary 

Submission for OMB Emergency 

Review; Comment Request 

October 17, 2005. 

The Department of Labor has 

submitted the following (see below) 

information collection request (ICR), 

utilizing emergency review procedures, 

to the Office of Management and Budget 

(OMB) for review and clearance in 

accordance with the Paperwork 

Reduction Act of 1995 (Pub. L. 104–13, 

44 U.S.C. Chapter 35). OMB approval 

has been requested by November 18, 

2005. A copy of this ICR, with 

applicable supporting documentation, 

may be obtained by contacting Darrin 

King at (202) 693–4129 (this is not a 

toll-free number) or emailing 

king.darrin@dol.gov. 

Comments and questions about the 

ICR listed below should be submitted to 

the Office of Information and Regulatory 

Affairs, Attn: OMB Desk Officer for the 

Department of Labor Center for FaithBased and Community Initiatives, Office 

of Management and Budget, Room 

10235, Washington, DC 20503 (202–

395–7316), and received 5 days prior to 

the requested OMB approval date. The 

Office of Management and Budget is 

particularly interested in comments 

which: 

• Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

• Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

• Enhance the quality, utility, and 

clarity of the information to be 

collected; and